STAMBPL1 depletion was found to induce apoptosis by promoting the degradation of the protein XIAP, suggesting that targeting STAMBPL1 might offer a promising therapeutic strategy for prostate cancer [23]. Here, STAMBPL1 is linked to prostate carcinoma.